RNA Viruses and Antibody Response
This Special Issue comprises 14 original studies and 2 reviews, and will serve as a platform to further the current knowledge of antibody responses against RNA virus infections.
Saved in:
| Format: | Online |
|---|---|
| Sprog: | engelsk |
| Udgivet: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Fag: | |
| Online adgang: | ONIX_20240514_9783725801107_137 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
| _version_ | 1869520383061786624 |
|---|---|
| collection | Directory of Open Access Books |
| description | This Special Issue comprises 14 original studies and 2 reviews, and will serve as a platform to further the current knowledge of antibody responses against RNA virus infections. |
| format | Online |
| id | doab-20.500.12854ir-137536 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1375362024-05-14T13:26:14Z RNA Viruses and Antibody Response Kam, Jason Yiu Wing SARS-CoV-2 HIV/AIDS SARS-CoV-2 vaccine Omicron variant neutralization titers third dose vaccine Chikungunya virus immunoinformatics B-cell epitopes peptides ELISA COVID-19 RBD immunogenicity mutant cohort study antibody waning seroreactivity electrochemiluminescence assay fixed-effect models nursing home epidemiology seroprevalence pre-vaccination nucleocapsid phosphoprotein monoclonal antibody recombinant protein cross-reactivity epitopes mapping antibody repertoires original antigenic sin immune imprinting repeated influenza exposures broadly neutralizing antibody influenza A H3N2 virus sotrovimab nirmatrelvir/ritonavir molnupiravir remdesivir human infection repeated infection HIV-1 RSV neutralizing antibody neutralization assay epitope specificity analysis of serum antibody specificity antibody dynamics vaccine protection time mathematical modeling multiple myeloma ritonavir-nirmatrelvir belantamab mafodotin T cell response breakthrough infection influenza antibody virus convalescent plasma meta-analysis randomized controlled trials mortality intensive care unit antibody response RNA viruses infection vaccination nucleocapsid protein spike protein n/a thema EDItEUR::P Mathematics and Science::PS Biology, life sciences This Special Issue comprises 14 original studies and 2 reviews, and will serve as a platform to further the current knowledge of antibody responses against RNA virus infections. 2024-05-14T13:26:02Z 2024-05-14T13:26:02Z 2024 book ONIX_20240514_9783725801107_137 9783725801107 9783725801091 https://directory.doabooks.org/handle/20.500.12854/137536 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/8702 https://mdpi.com/books/pdfview/book/8702 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0109-1 10.3390/books978-3-7258-0109-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725801107 9783725801091 224 open access |
| spellingShingle | SARS-CoV-2 HIV/AIDS SARS-CoV-2 vaccine Omicron variant neutralization titers third dose vaccine Chikungunya virus immunoinformatics B-cell epitopes peptides ELISA COVID-19 RBD immunogenicity mutant cohort study antibody waning seroreactivity electrochemiluminescence assay fixed-effect models nursing home epidemiology seroprevalence pre-vaccination nucleocapsid phosphoprotein monoclonal antibody recombinant protein cross-reactivity epitopes mapping antibody repertoires original antigenic sin immune imprinting repeated influenza exposures broadly neutralizing antibody influenza A H3N2 virus sotrovimab nirmatrelvir/ritonavir molnupiravir remdesivir human infection repeated infection HIV-1 RSV neutralizing antibody neutralization assay epitope specificity analysis of serum antibody specificity antibody dynamics vaccine protection time mathematical modeling multiple myeloma ritonavir-nirmatrelvir belantamab mafodotin T cell response breakthrough infection influenza antibody virus convalescent plasma meta-analysis randomized controlled trials mortality intensive care unit antibody response RNA viruses infection vaccination nucleocapsid protein spike protein n/a thema EDItEUR::P Mathematics and Science::PS Biology, life sciences RNA Viruses and Antibody Response |
| title | RNA Viruses and Antibody Response |
| title_full | RNA Viruses and Antibody Response |
| title_fullStr | RNA Viruses and Antibody Response |
| title_full_unstemmed | RNA Viruses and Antibody Response |
| title_short | RNA Viruses and Antibody Response |
| title_sort | rna viruses and antibody response |
| topic | SARS-CoV-2 HIV/AIDS SARS-CoV-2 vaccine Omicron variant neutralization titers third dose vaccine Chikungunya virus immunoinformatics B-cell epitopes peptides ELISA COVID-19 RBD immunogenicity mutant cohort study antibody waning seroreactivity electrochemiluminescence assay fixed-effect models nursing home epidemiology seroprevalence pre-vaccination nucleocapsid phosphoprotein monoclonal antibody recombinant protein cross-reactivity epitopes mapping antibody repertoires original antigenic sin immune imprinting repeated influenza exposures broadly neutralizing antibody influenza A H3N2 virus sotrovimab nirmatrelvir/ritonavir molnupiravir remdesivir human infection repeated infection HIV-1 RSV neutralizing antibody neutralization assay epitope specificity analysis of serum antibody specificity antibody dynamics vaccine protection time mathematical modeling multiple myeloma ritonavir-nirmatrelvir belantamab mafodotin T cell response breakthrough infection influenza antibody virus convalescent plasma meta-analysis randomized controlled trials mortality intensive care unit antibody response RNA viruses infection vaccination nucleocapsid protein spike protein n/a thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | SARS-CoV-2 HIV/AIDS SARS-CoV-2 vaccine Omicron variant neutralization titers third dose vaccine Chikungunya virus immunoinformatics B-cell epitopes peptides ELISA COVID-19 RBD immunogenicity mutant cohort study antibody waning seroreactivity electrochemiluminescence assay fixed-effect models nursing home epidemiology seroprevalence pre-vaccination nucleocapsid phosphoprotein monoclonal antibody recombinant protein cross-reactivity epitopes mapping antibody repertoires original antigenic sin immune imprinting repeated influenza exposures broadly neutralizing antibody influenza A H3N2 virus sotrovimab nirmatrelvir/ritonavir molnupiravir remdesivir human infection repeated infection HIV-1 RSV neutralizing antibody neutralization assay epitope specificity analysis of serum antibody specificity antibody dynamics vaccine protection time mathematical modeling multiple myeloma ritonavir-nirmatrelvir belantamab mafodotin T cell response breakthrough infection influenza antibody virus convalescent plasma meta-analysis randomized controlled trials mortality intensive care unit antibody response RNA viruses infection vaccination nucleocapsid protein spike protein n/a thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | ONIX_20240514_9783725801107_137 |